Clinical Trials | June 04, 2024
Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Merck shared updates on the company’s oncology pipeline and focused R&D approach
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Greg was also central to the planning, design, and construction of this facility
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Establishing Asymchem’s first manufacturing footprint in Europe
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Subscribe To Our Newsletter & Stay Updated
